Cat. No.: HY-14440

Copy Link Print Information

MP7

(Synonyms: PDK1 inhibitor)

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

MP7 (PDK1 inhibitor) is a phosphoinositide-dependent kinase-1 (PDK1) inhibitor.

For research use only. We do not sell to patients.

Purity: 99.33%
CAS No.: 1001409-50-2
Formula: C₂₈H₂₂F₂N₄O₄
Molecular Weight:516.50

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

MP7 Chemical Structure

CAS No.: 1001409-50-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

MP7 (PDK1 inhibitor) is a phosphoinositide-dependent kinase-1 (PDK1) inhibitor.

IC₅₀ & Target

PDK1^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	>30 μM Compound: MP-7	Cytotoxicity against human 786-0 cells measured after 72 hrs by MTT assay Cytotoxicity against human 786-0 cells measured after 72 hrs by MTT assay	[PMID: 34624821]
A-427	EC₅₀	>9 μM Compound: 11	Antiproliferative activity against human A427 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay Antiproliferative activity against human A427 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay	[PMID: 23448267]
A549	EC₅₀	>9 μM Compound: 11	Antiproliferative activity against human A549 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay Antiproliferative activity against human A549 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay	[PMID: 23448267]
A673	IC₅₀	>30 μM Compound: MP-7	Cytotoxicity against human A673 cells measured after 72 hrs by MTT assay Cytotoxicity against human A673 cells measured after 72 hrs by MTT assay	[PMID: 34624821]
BEAS-2B	IC₅₀	96.36 μM Compound: 6; MP7	Antiproliferative against human BEAS-2B cells measured after 48 hrs by CCK8 assay Antiproliferative against human BEAS-2B cells measured after 48 hrs by CCK8 assay	[PMID: 36603508]
BT-474	EC₅₀	>9 μM Compound: 11	Antiproliferative activity against human BT474 cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay Antiproliferative activity against human BT474 cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay	[PMID: 23448267]
CAKI-1	IC₅₀	>30 μM Compound: MP-7	Cytotoxicity against human CAKI-1 cells measured after 72 hrs by MTT assay Cytotoxicity against human CAKI-1 cells measured after 72 hrs by MTT assay	[PMID: 34624821]
HCT-116	EC₅₀	>9 μM Compound: 11	Antiproliferative activity against human HCT116 cells harboring PI3KCA/KRAS double mutant after 72 hrs by ATP ViaLight assay Antiproliferative activity against human HCT116 cells harboring PI3KCA/KRAS double mutant after 72 hrs by ATP ViaLight assay	[PMID: 23448267]
HCT-116	IC₅₀	>30 μM Compound: MP-7	Cytotoxicity against human HCT-116 cells measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 34624821]
HFL1	IC₅₀	64.79 μM Compound: 6; MP7	Antiproliferative against HLF1 cells measured after 48 hrs by CCK8 assay Antiproliferative against HLF1 cells measured after 48 hrs by CCK8 assay	[PMID: 36603508]
HSC-T6	IC₅₀	36.23 μM Compound: 6; MP7	Antiproliferative against rat HSC-T6 cells measured after 48 hrs by CCK8 assay Antiproliferative against rat HSC-T6 cells measured after 48 hrs by CCK8 assay	[PMID: 36603508]
IGROV-1	IC₅₀	>30 μM Compound: MP-7	Cytotoxicity against human IGROV-1 cells measured after 72 hrs by MTT assay Cytotoxicity against human IGROV-1 cells measured after 72 hrs by MTT assay	[PMID: 34624821]
LNCaP	EC₅₀	>9 μM Compound: 11	Antiproliferative activity against PTEN-deficient human LNCAP cells after 72 hrs by ATP ViaLight assay Antiproliferative activity against PTEN-deficient human LNCAP cells after 72 hrs by ATP ViaLight assay	[PMID: 23448267]
LS-513	EC₅₀	>9 μM Compound: 11	Antiproliferative activity against human LS513 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay Antiproliferative activity against human LS513 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay	[PMID: 23448267]
MCF7	EC₅₀	>9 μM Compound: 11	Antiproliferative activity against human MCF7 cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay Antiproliferative activity against human MCF7 cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay	[PMID: 23448267]
MCF7	IC₅₀	>30 μM Compound: MP-7	Cytotoxicity against human MCF7 cells measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells measured after 72 hrs by MTT assay	[PMID: 34624821]
MDA-MB-231	EC₅₀	>9 μM Compound: 11	Antiproliferative activity against human MDA-MB-231 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay Antiproliferative activity against human MDA-MB-231 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay	[PMID: 23448267]
MDA-MB-453	EC₅₀	>9 μM Compound: 11	Antiproliferative activity against human MDA-MB-453 cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay Antiproliferative activity against human MDA-MB-453 cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay	[PMID: 23448267]
NCI-H1437	EC₅₀	>9 μM Compound: 11	Antiproliferative activity against human NCI-H1437 cells after 72 hrs by ATP ViaLight assay Antiproliferative activity against human NCI-H1437 cells after 72 hrs by ATP ViaLight assay	[PMID: 23448267]
NCI-H446	EC₅₀	>9 μM Compound: 11	Antiproliferative activity against PTEN-deficient human NCI-H446 cells after 72 hrs by ATP ViaLight assay Antiproliferative activity against PTEN-deficient human NCI-H446 cells after 72 hrs by ATP ViaLight assay	[PMID: 23448267]
NCI-H69	IC₅₀	13.9 μM Compound: MP-7	Cytotoxicity against human NCI-H69 cells measured after 72 hrs by MTT assay Cytotoxicity against human NCI-H69 cells measured after 72 hrs by MTT assay	[PMID: 34624821]
NCI-H82	IC₅₀	>30 μM Compound: MP-7	Cytotoxicity against human NCI-H82 cells measured after 72 hrs by MTT assay Cytotoxicity against human NCI-H82 cells measured after 72 hrs by MTT assay	[PMID: 34624821]
NRK-49F	IC₅₀	40.39 μM Compound: 6; MP7	Antiproliferative against rat NRK-49F cells measured after 48 hrs by CCK8 assay Antiproliferative against rat NRK-49F cells measured after 48 hrs by CCK8 assay	[PMID: 36603508]
PC-3	EC₅₀	>9 μM Compound: 11	Antiproliferative activity against PTEN-deficient human PC3 cells after 72 hrs by ATP ViaLight assay Antiproliferative activity against PTEN-deficient human PC3 cells after 72 hrs by ATP ViaLight assay	[PMID: 23448267]
PC-3	IC₅₀	>30 μM Compound: MP-7	Cytotoxicity against human PC-3 cells measured after 72 hrs by MTT assay Cytotoxicity against human PC-3 cells measured after 72 hrs by MTT assay	[PMID: 34624821]
Rec1	IC₅₀	>30 μM Compound: MP-7	Cytotoxicity against human REC1 cells measured after 72 hrs by MTT assay Cytotoxicity against human REC1 cells measured after 72 hrs by MTT assay	[PMID: 34624821]
SK-N-MC	IC₅₀	>30 μM Compound: MP-7	Cytotoxicity against human SK-N-MC cells measured after 72 hrs by MTT assay Cytotoxicity against human SK-N-MC cells measured after 72 hrs by MTT assay	[PMID: 34624821]
T47D	EC₅₀	>9 μM Compound: 11	Antiproliferative activity against human T47D cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay Antiproliferative activity against human T47D cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay	[PMID: 23448267]
TC-32	IC₅₀	13.9 μM Compound: MP-7	Cytotoxicity against human TC-32 cells measured after 72 hrs by MTT assay Cytotoxicity against human TC-32 cells measured after 72 hrs by MTT assay	[PMID: 34624821]
U-87MG ATCC	EC₅₀	>9 μM Compound: 11	Antiproliferative activity against PTEN-deficient human U87 cells after 72 hrs by ATP ViaLight assay Antiproliferative activity against PTEN-deficient human U87 cells after 72 hrs by ATP ViaLight assay	[PMID: 23448267]
U-87MG ATCC	IC₅₀	>30 μM Compound: MP7	Antiproliferative activity against human U87MG cells after 72 hrs Antiproliferative activity against human U87MG cells after 72 hrs	[PMID: 27123901]
UMC-11	EC₅₀	>9 μM Compound: 11	Antiproliferative activity against human UMC11 cells after 72 hrs by ATP ViaLight assay Antiproliferative activity against human UMC11 cells after 72 hrs by ATP ViaLight assay	[PMID: 23448267]

In Vitro

Cell counting of U87MG-derived glioma stem cells (GSCs) confirms that Alisertib and, to a minor extent, MP7 (PDK1 inhibitor) are able to decrease the number of viable cells. When combined together, GSC viability is further reduced with respect to single-treated cells. As observed in U87MG cells, when used at the highest concentrations (i.e., 1.5 μM Alisertib and 2.5 μM MP7), a significant enhancement in the number of dead cells is evidenced. Following 72 h treatment, MP7 alone does not show a significant inhibition of glioblastoma multiforme (GBM) proliferation. MP7 has been shown to have only minimal effects on monolayer cell growth in several cancer cell lines, with IC₅₀ values in the micromolar range^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1001409-50-2
Appearance Solid
Molecular Weight 516.50
Formula C₂₈H₂₂F₂N₄O₄
Color Light yellow to yellow
SMILES

O=C(C1=CC=CN(CC2=CC=C(F)C(F)=C2)C1=O)N[C@H](C3=CC=CC=C3)COC4=CC=C(N5)C(NC5=O)=C4
Synonyms

PDK1 inhibitor
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

Cell Rep Med

Insulin- and exercise-induced phosphoproteomics of human skeletal muscle identify REPS1 as a regulator of muscle glucose uptake. [Abstract]

2025 Jun 17;6(6):102163. PMID: 40482643
EMBO J

The global phosphorylation landscape of mouse oocytes during meiotic maturation. [Abstract]

2024 Oct;43(20):4752-4785. PMID: 39256562

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (193.61 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9361 mL

9.6805 mL

19.3611 mL

5 mM

0.3872 mL

1.9361 mL

3.8722 mL

10 mM

0.1936 mL

0.9681 mL

1.9361 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.75 mg/mL (5.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.75 mg/mL (5.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[1]

The human GBM cells (i.e., U87MG, U343MG, or ANGM-CSS) or the respective GSCs are seeded and incubated for the indicated times with the indicated concentrations of SA16 (1 nM to 100 μM), MP7 (2.5 nM, 25 nM, 250 nM and 2.5 μM), or Alisertib. When indicated, cells are treated with MP7 and Alisertib in combination. To verify GSC chemoresistance, U87MG or GSCs are incubated with 50 μM TMZ for 72 h. For the long-term treatment of cells, NSC or complete medium containing drugs is replaced every 3 days. Cell proliferation is determined using the MTS assay: the dehydrogenase activity in active mitochondria reduces MTS to the soluble formazan product, whose absorbance at 490 nm is measured with an automated plate reader. The mean background from each test condition is subtracted, and the data are expressed as the percentage of untreated cells (control). IC₅₀ values are derived from the sigmoid dose-response curve. The percentage of inhibition is calculated as 100% minus the percentage of cell proliferation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Daniele S, et al. Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells. ACS Chem Neurosci. 2017 Jan 18;8(1):100-114. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9361 mL	9.6805 mL	19.3611 mL	48.4027 mL
	5 mM	0.3872 mL	1.9361 mL	3.8722 mL	9.6805 mL
	10 mM	0.1936 mL	0.9681 mL	1.9361 mL	4.8403 mL
	15 mM	0.1291 mL	0.6454 mL	1.2907 mL	3.2268 mL
	20 mM	0.0968 mL	0.4840 mL	0.9681 mL	2.4201 mL
	25 mM	0.0774 mL	0.3872 mL	0.7744 mL	1.9361 mL
	30 mM	0.0645 mL	0.3227 mL	0.6454 mL	1.6134 mL
	40 mM	0.0484 mL	0.2420 mL	0.4840 mL	1.2101 mL
	50 mM	0.0387 mL	0.1936 mL	0.3872 mL	0.9681 mL
	60 mM	0.0323 mL	0.1613 mL	0.3227 mL	0.8067 mL
	80 mM	0.0242 mL	0.1210 mL	0.2420 mL	0.6050 mL
	100 mM	0.0194 mL	0.0968 mL	0.1936 mL	0.4840 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

MP7

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) MP7

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MP7

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) MP7

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MP7 Related Classifications

HY-14440 Related Classifications